Relative potencies of Flutamide and Casodex: Preclinical studies

Endocrine-Related Cancer

Volumn 3, Issue 3, 1996, Pages 229-241

  Luo, S ^a   Martel, C ^a   LeBlanc, G ^a   Candas, B ^a   Singh, S M ^a   Labrie, C ^a   Simard, J ^a   Belanger A ^a   Labrie, F ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; EM 879; FLUTAMIDE; METRIBOLONE; NILUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; RAT; SEMINAL VESICLE; TREATMENT OUTCOME;

EID: 0029910874     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030229     Document Type: Article

References (58)

1. Bélanger A, Caron S & Picard V 1980 Simultaneous radioimmunoassay of progestins, androgens and estrogens in adult rat testis. Journal of Steroid Biochemistry 13 185-190.
2. Bélanger A, Labrie F, Dupont A, Brochu M & Cusan L 1988 Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma. Clinical and Investigative Medicine 11 321-326.
3. Bélanger A, Labrie F, Monfette G, Dupont A & Caron S 1989 Measurement of non conjugated C-19 steroids as well as C-19 steroid glucuronides in plasma and tissue. First International Symposium on Steroid Formation, Degradation and Action in Peripheral, Normal and Neoplastic Tissues. Abstract no. 35.
4. Chandolia RK, Weinbauer GF, Behre HM & Nieschlag E 1991 Evaluation of peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. Journal of Steroid Biochemistry and Molecular Biology 38 367-375.
5. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E & Kennealey GT 1995 Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46 849-855.
6. Crawford D, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
7. Denis L, Carneiro de Moura JL, Bono A, Sylvester R, Wheeton R, Newling D & Pauno MD 1993 Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 119-129.
8. Dorfman RI 1971 Antiandrogens. Proceedings of the Third International Congress on Hormonal Steroids. Abstract no. 995.
9. Fiszer-Szafarz B, Skafarz D & Guevara de Murillo A 1981 A general, fast and sensitive micromethod for DNA determination: application to rat and mouse liver, rat hepatoma, human leukocytes, chicken fibroblasts and yeast cells. Analytical Biochemistry 110 165-170.
10. Furhmann U, Bengtson C, Repenthin G & Schillinger E 1992 Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of CAT expression by anti-androgens. Journal of Steroid Biochemistry and Molecular Biology 42787-793.
11. Furr BJA 1989 Casodex (ICI 176334) - A new, pure, peripherally selective antiandrogen: preclinical studies. Hormone Research 32 (Suppl) 69-76.
12. Furr BJA 1990 Casodex: preclinical studies. European Urology 18 2-9.
13. Furr BJA & Milsted RAV 1988 LH-RH analogues in cancer treatment. In Endocrine Management of Cancer: 2. Contemporary Therapy, pp 16-29. Ed B Stoll. Karger: Basel.
14. Furr BJA & Tucker H 1996 The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13-25.
15. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterson G & Tucker H 1987 ICI 176,334: a novel non-steroidal peripherally selective antiandrogen. Journal of Endocrinology 113 R7-R9.
16. Gittes RF 1991 Carcinoma of the prostate. New England Journal of Medicine 24 236-245.
17. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Tremblay M & Labrie F 1992 Incidence of liver toxicity with the use of flutamide in prostate cancer patients. American Journal of Medicine 5 465-470.
18. Huggins C & Hodges CV 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-307.
19. Juniewicz RE, McCarthy M, Lemp BM, Barbolt TA, Shaw C, Hollenbaugh DM, Winneker RC, Reel JR & Batzold FH 1990 The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs. Endocrinology 126 2625-2634.
20. Katchen B & Buxbaum S 1975 Disposition of a new, nonsteroid, antiandrogen, α,α,α-trifluoro-2-niethyl-4′- nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. Journal of Clinical Endocrinology and Metabolism 41 373-379.
21. Kennealey GT & Furr BJ 1991 Use of the nonsteroidal antiandrogen Casodex in advanced prostatic carcinoma. Urology Clinics of North America 18 99-110.
22. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118.
23. Labrie F 1993 Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 3816-3827.
24. Labrie F 1995 Endocrine therapy of prostate cancer optimal form and timing. Journal of Clinical Endocrinology and Metabolism 80 1066-1071.
25. Labrie F & Veilleux R 1986 A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8 293-300.
26. Labrie F & Veilleux R 1988 Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. Journal of the National Cancer Institute 80 966-970.
27. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A & Ranaud JP 1980 Antifertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
28. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas ATA, Raynaud JP & Husson JM 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Journal of Clinical and Investigative Medicine 5 267-275.
29. Labrie F, Dupont A, Bélanger A, Lacourcière Y, Raynaud JP, Husson JM, Gareau J, Fazekas AT, Sandow J, Monfette G, Girard JG, Emond J & Houle JG 1983 New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4 579-594.
30. Labrie F, Dupont A & Bélanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology, pp 193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: JB Lippincott.
31. Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J & Monfette G 1986 Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews 7 67-74.
32. Labrie C, Cusan L, Plante M, Lapointe S & Labrie F 1987 Analysis of the androgenic activity of synthetic 'progestins' currently used for the treatment of prostate cancer. Journal of Steroid Biochemistry 28 379-384.
33. Labrie F, Veilleux R & Fournier A 1988a Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture. Molecular and Cellular Endocrinology 58 207-211.
34. Labrie F, Veilleux R & Fournier A 1988b Low androgen levels induce the development of androgen- hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture. Journal of the National Cancer Institute 80 1138-1147.
35. Labrie C, Simard J, Zhao HF, Pelletier G & Labrie F 1990 Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Molecular and Cellular Endocrinology 68 169-179.
36. Labrie F, Simard J, Luu-The V, Pelletier G, Belghmi K & Bélanger A 1994 Structure, regulation and role of 3β- hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues. In Hormone, Enzymes and Receptors, pp 451-474. Eds MC Sheppard & PM Stewart. Baillière's Clinical Endocrinology and Metabolism. London: Ballière Tindall.
37. Labrie F, Cusan L, Gomez JL, Diamond P & Candas B 1995 Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. Journal of Clinical Endocrinology and Metabolism 80 2002-2013.
38. Lacoste D, St-Arnaud R, Bélanger A & Labrie F 1988 A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Molecular and Cellular Endocrinology 56 141-147.
39. 2]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog. Molecular and Cellular Endocrinology 67 131-138.
40. Luo S, Chen C, Martel C, LeBlanc G, Candas B & Labrie F 1996 Comparison of the biological activities of Flutamide and Casodex in the rat. Proceedings of the Endocrine Society, San Francisco, CA, p 152, Abstract No P1-69.
41. Luthy I, Bégin D & Labrie F 1988 Androgenic activity of synthetic progestins and spironolactone in androgen- sensitive mouse mammary carcinoma (Shionogi) cells in culture. Journal of Steroid Biochemistry 31 845-852.
42. Marchetti B & Labrie F 1988 Characteristics of Flutamide action on prostatic and testicular functions in the rat. Journal of Steroid Biochemistry 29 691-698.
43. Marquardt DW 1963 An algorithm for least squares estimation of non-linear parameters. Journal of the Society for Industrial and Applied Mathematics 11 431-441.
44. Moguilewsky M, Fiet J, Tournemine C & Raynaud JP 1987 Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of Steroid Biochemistry 24 139-146.
45. Mowszowicz I, Bieber DE, Chung KW, Bullock L & Bardin CW 1974 Synandrogenic and antiandrogenic effect of progestins: comparison with non-progestational antiandrogens. Endocrinology 95 1589-1599.
46. Neri R, Monahan MD, Meyer JG, Afonso BA & Tabachnick IA 1967 Biological studies of an antiandrogen (SH-714). European Journal of Pharmacology 1 438-444.
47. Neri R, Florance K, Koziol P & Cleave SV 1972 A biological profile of nonsteroidal antiandrogen, SCH13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 91 427-437.
48. Ojasso T 1987 Nilutamide. Drugs of the Future 12 763-770.
49. Parker SL, Tong T, Bolden S & Wingo PA 1996 Cancer Statistics 1996. CA Cancer Journal for Clinicians 65 5-27.
50. Plante M, Lapointe S & Labrie F 1988 Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. Journal of Steroid Biochemistry 31 61-64.
51. Poyet P & Labrie F 1985 Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Molecular and Cellular Endocrinology 42 283-288.
52. Raynaud JP 1988 Antiandrogens in combination with LH-RH agonists in prostate cancer. American Journal of Clinical Oncology 11 S132-S147.
53. Rodbard D 1974 Apparent positive cooperative effect in cyclic AMP and corticosteroid production by isolated adrenal cells in response to ACTH analogs. Endocrinology 94 1427-1437.
54. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J & Kolvenbag G 1995 A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45 745-752.
55. Snyder BW, Winneker RC & Batzold FH 1989 Endocrine profile of Win 49,596 in the rat: a novel androgen receptor antagonist. Journal of Steroid Biochemistry 33 1127-1132.
56. Sufrin G & Coffey DS 1976 Flutamide. Mechanism of action of a new steroidal antiandrogen. Investigative Urology 13 429-435.
57. Vershelst J, Denis L, Van Vliet P, Van Poppel V, Braeckman J, Van Cangh P, Mattelaer J, D'Hulster D & Mahler C 1994 Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clinical Endocrinology 41 525-530.
58. Winneker RC, Wagner MM & Batzold FH 1989 Studies on the mechanism of action of Win 49,596: a steroidal androgen receptor antagonist. Journal of Steroid Biochemistry 33 1133-1138.